Anti-NKG2D chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics)

N/A

Report date: 2024/07/26 16:09:22

Base Information

Drug NameAnti-NKG2D chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics)
Drug Alias NameNKG2D CAR NK cell therapy (Hangzhou Cheetah Cell Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNatural killer cell replacementsNKG2-D type II integral membrane protein modulators
TargetsNKG2-D type II integral membrane protein
Therapy Area/IndicationsOvarian NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsOvarian NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A